Stifel Nicolaus Sticks to Their Hold Rating for Mallinckrodt

Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Mallinckrodt (NYSE: MNK) today and set a price target of $18. The company’s shares opened today at $18.84.

According to TipRanks.com, Samimy is a 4-star analyst with an average return of 11.8% and a 54.5% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Cara Therapeutics, and TherapeuticsMD.

Mallinckrodt has an analyst consensus of Hold, with a price target consensus of $17.89.

See today’s analyst top recommended stocks >>

Mallinckrodt’s market cap is currently $1.61B and has a P/E ratio of 1.03. The company has a Price to Book ratio of 0.25.

Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines.